

This is the peer reviewed version of the following article:

Epidemiology, Assessment, and Management of Excess Abdominal Fat in Persons with HIV Infection / Moyle, G.; Moutschen, M.; Martínez, E.; Domingo, P.; Guaraldi, Giovanni; Raffi, F.; Behrens, G.; Reiss, P.. - In: AIDS REVIEWS. - ISSN 1139-6121. - STAMPA. - 12:1(2010), pp. 3-14.

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

03/05/2026 22:14

(Article begins on next page)

Epidemiology, Assessment, and Management of Excess Abdominal Fat in Persons with HIV Infection

Graeme Moyle¹, Michel Moutschen², Esteban Martínez³, Pere Domingo⁴, Giovanni Guaraldi⁵, François Raffi⁶, Georg Behrens⁷ and Peter Reiss⁸

¹Chelsea and Westminster Hospital, London, UK; ²Liège AIDS Reference Center, CHU Liège - GIGA Research ULg, Belgium; ³Hospital Clinic and University of Barcelona, Barcelona, Spain; ⁴Infectious Diseases Unit, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁵Department of Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia School of Medicine, Modena, Italy; ⁶Infectious Diseases Department, University Hospital, Hotel-Dieu, Nantes, France; ⁷Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany; ⁸Center for Poverty-related Communicable Diseases (CPCD), Department of Internal Medicine, Center for Infection and Immunity (CINIMA), Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Abstract

Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased abdominal circumference and visceral adiposity were first recognized in the late 1990s, soon after the advent of effective combination antiretroviral therapy. Visceral adiposity is commonly associated with metabolic abnormalities including low HDL-cholesterol, raised triglycerides, insulin resistance, and hypertension, a constellation of risk factors for cardiovascular disease and diabetes mellitus known as “the metabolic syndrome”. Medline and conference abstracts were searched to identify clinical research on factors associated with visceral adiposity and randomized studies of management approaches. Data were critically reviewed by physicians familiar with the field. A range of host and lifestyle factors as well as antiretroviral drug choice were associated with increased visceral adiposity. Management approaches included treatment switching and metformin, both of which have shown benefit for insulin-resistant individuals with isolated fat accumulation. Testosterone supplements may also have benefits in a subset of individuals. Supra-physiological doses of recombinant human growth hormone and the growth hormone releasing hormone analog tesamorelin both significantly and selectively reduce visceral fat over 12-24 weeks; however, the benefits are only maintained if dosing is continued. In summary, the prevention and management of visceral adiposity remains a substantial challenge in clinical practice. (AIDS Rev. 2010;12:3-14)

Corresponding author: Graeme Moyle, gm@moyleg.demon.co.uk

Key words

Visceral adiposity. Lipodystrophy. HIV. Metabolic syndrome. Metformin. Tesamorelin.

Introduction

Outcomes for people in developed countries with HIV infection have dramatically changed with the availability of effective combination antiretroviral treatment

(cART). HIV has become a chronic, manageable infection and management of persons with HIV has refocused on the adverse effects of HIV infection, immune restoration syndromes, and off-target effects of antiretroviral medications. Many common, prevalent diseases of aging appear increased in prevalence and earlier in onset in persons with HIV infection than in the uninfected population.

Soon after the benefits of cART were observed, the FDA warned against glucose intolerance and diabetes mellitus (DM) risk in patients receiving protease inhibitors (PI)¹ and patient networks began reporting morphologic abnormalities, notably increased abdominal

Correspondence to:

Graeme Moyle
Chelsea and Westminster Hospital
369 Fulham Rd
London, SW10 9NH, United Kingdom
E-mail: gm@moyleg.demon.co.uk

circumference². Subsequently, case reports and small case series suggested an increase incidence of cardiovascular (CV) events in patients with HIV receiving cART^{3,4}. Despite improvements in the convenience of administration and the metabolic safety profile of cART, concerns about morphologic change, CV risk, and DM remain prevalent.

Our understanding of CV risk and the pathogenesis of atherosclerosis has also changed. Beyond lifestyle and genetic factors, immune activation and inflammation have been recognized as important factors in the pathogenesis of atherosclerosis. Similarly, the adipocyte has shifted from being a passive storage cell for triglycerides to a secretory organ of adipokines such as leptin⁵, adiponectin, and inflammatory factors such as tumor necrosis factor alpha⁶. The role of central adiposity and visceral adipose tissue (VAT) in CV and DM risk has been recognized independently and through the metabolic syndrome⁷⁻¹⁰.

Visceral adiposity is both a highly stigmatizing clinical event in persons with HIV and a risk factor for future disease. Subjects with HIV infection have higher VAT than HIV-negative controls with the same body mass index (BMI)¹¹. Additionally, HIV infection, elevated VAT, and elevated C-reactive protein are significantly associated, linking HIV and VAT to inflammatory events¹².

The goal of this review is to summarize recent data regarding HIV infection and accumulation of central adiposity and, specifically, visceral fat, and to discuss clinical issues regarding the routine evaluation of VAT as well as preventive and therapeutic approaches.

Methods for assessing visceral adipose tissue

Lipohypertrophy may include fat accumulation in the abdominal cavity (VAT), dorso-cervical fat pad, breasts, and other lipomas. Waist circumference independently contributes to CV risk and DM risk¹³. It is also recognized in definitions of the metabolic syndrome as being relevant to CV and DM risk. A range of waist circumference values have been suggested by groups such as the International Diabetic Federation (IDF), who define central obesity as waist circumference > 94 cm for Caucasian men and > 80 cm for Caucasian women, with ethnicity specific values for other groups¹⁴, and the National Cholesterol Education Program (NCEP), which defines abdominal obesity as waist circumference > 102 cm for men and > 88 cm for women¹⁵. However, as persons with HIV commonly have lower subcutaneous adipose tissue (SAT), simple abdominal

circumference measurements may underestimate the amount of harmful VAT¹⁶.

Visceral adipose tissue consists of adipose tissue distributed in the three body cavities: intrathoracic, intraabdominal, and intrapelvic. However, most authors refer to VAT as synonymous to intraabdominal adipose tissue, with a radiological range from 5 cm below L4-L5 to the slice corresponding to the superior border of the liver¹⁷⁻²¹.

Imaging techniques are the most precise and reliable methods for a qualitative and quantitative VAT analysis. Computed tomography (CT) and, especially, magnetic resonance imaging (MRI), the gold standard technique, provide methods to non-invasively estimate VAT safely and accurately²²⁻²⁶. The MRI VAT measurements have been reported as either area values (cm²) obtained from a single image, or as volume values (cm³) derived using tissue area measurements from multiple images. Several MRI techniques and automatic or semi-automated analyses of VAT have been reported^{22,27-31}.

The relatively high cost of whole-body scans for MRI and the exposure to radiation for CT led to the use of single-slice studies for this application³². Some studies have reported a good correlation between VAT area measured in a single slice and VAT volume measured by using multiple slices^{33,34}, whereas others have not³⁵. The cut-off point to define visceral obesity has been suggested as 130 cm² in men and 110 cm² for women³⁶. The coefficients of variation for VAT measurements by MRI are ~ 9 to 18%³⁷⁻⁴⁰ and by CT are ~ 2%⁴¹. The lower coefficient of variation of CT is usually ascribed to a shorter image acquisition time, and CT is thus less vulnerable to image artifacts produced by peristaltic gastrointestinal tract movement⁴².

Abdominal ultrasound measurement has also been reported to provide good and reproducible calculations for VAT, suggesting ultrasonography as a promising technique based upon low cost and easy application. It has been found that pre-peritoneal and subcutaneous fat depositions, as measured by ultrasonography, correlated positively with the visceral fat area measured by CT ($r = 0.746$) with a coefficient of variation of less than 6%⁴³⁻⁴⁶. Reproducibility across operators, machines, and sites limit the application of ultrasound in clinical studies.

Dual-energy X-ray absorptiometry (DXA) systems provide whole-body and regional estimates of fat mass, and the DXA technique is a widely used method owing to its ease of use, availability, and low radiation exposure. The advantages of DXA include good accuracy

and reproducibility. Disadvantages of DXA include a small amount of radiation, the scanning bed or stretcher has an upper weight limit, and the whole-body field-of-view cannot accommodate large individuals. A DXA provides estimates of trunk and limb fat and as such does not provide sufficient information to reliably evaluate VAT^{47,48}.

Bioelectrical impedance analysis (BIA) provides a safe and low-cost estimate of total body water and total body fat-free mass. The multi-segmental BIA approach may be used to assess limb fat and total body fat, but has limited applicability with regards VAT, and its output may be influenced by other regional changes in fat such as lipoatrophy or obesity^{49,50}. More recently, a modified regional BIA technique has been used to estimate VAT, which correlated significantly with VAT by CT ($r = 0.88$)⁵¹.

Correlation exists between single-slice CT measurement of VAT and anthropometric measurements in HIV-positive patients with central fat accumulation⁵². Both waist circumference and waist-to-hip ratio (WHR) correlated with VAT in men but not in women. In nonobese men, the correlation between VAT measured by MRI and waist circumference is also high ($r = 0.77$)⁴⁸, with similar correlations reported in HIV-positive subjects⁵³.

The prevalence of central adiposity in HIV populations

An initial lack of objective definitions of lipoatrophy and lipohypertrophy hindered objective evaluation of morphologic changes. Thinning of the arms and legs may result in the appearance of abdomen prominence, and, with increased waist circumference, extremities may appear to be smaller. Furthermore, central fat accumulation is common in the general population and an increase in weight, abdominal girth, and VAT is a normal component of aging in the general population⁵⁴. A subsequent case definition of lipodystrophy excluded isolated central adiposity from the definition⁵⁵.

Initial prevalence studies were cross-sectional in nature and typically lacked objective assessments. The larger prevalence studies reported central adiposity in 30-62% of cART recipients⁵⁶⁻⁶⁰. Studies published to March, 2007 involving more than 100 patients and reporting subjective outcomes relating to central fat accumulation found prevalence estimates ranging from 13 to 58% (median 30%) of HIV-positive patients⁶¹. A recent cross-sectional French study, with more than 2,000 HIV-positive patients, showed that a waist circumference indicative of abdominal adiposity by IDF

and NCEP ATP III definitions^{15,16} is a common and increasing problem. Increased waist circumference was more common in women than men, and its prevalence was higher in recent recipients of cART. The prevalence of abdominal adiposity was 24-53% in women and 13-29% in men who started cART before 2005, and 43-77% in women and 12-38% in men who started cART after 2005, according to IDF and NCEP ATP III definitions, respectively⁶².

The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study, a cross-sectional study, examined fat changes in men and women based on concordance between the patient's self-report of a decrease or increase over the previous five years and a researcher's assessment. Approximately 30% of men and 50% of women with HIV had abdominal adiposity. In the FRAM study, MRI measurements of VAT and SAT showed HIV-positive men⁶³ and women⁶⁴ had more fat loss than HIV-negative controls in peripheral and central depots. Among HIV-positive men, peripheral lipoatrophy was more frequent than in controls (38.3 vs. 4.6%; $p < 0.001$), whereas central adiposity was less frequent (40.2 vs. 55.9%; $p = 0.001$), and the presence of central adiposity was not positively associated with peripheral lipoatrophy (OR: 0.71; 95% CI: 0.47-1.06; $p = 0.10$)⁶³. Among HIV-positive women, peripheral lipoatrophy was more frequent than in controls (28 vs. 4%; $p < 0.001$), whereas central lipohypertrophy was similar (62 vs. 63%), and those with central lipohypertrophy were less likely to have peripheral lipoatrophy (OR: 0.39; 95% CI: 0.20-0.75; $p = 0.006$) than those without central lipohypertrophy. On MRI, HIV-positive women with clinical peripheral lipoatrophy had less SAT in peripheral and central sites and less VAT than HIV-positive women without peripheral lipoatrophy. Compared with controls, HIV-positive women had less SAT in the legs, regardless of the presence or absence of lipoatrophy; however, those without lipoatrophy had more VAT and upper-trunk SAT than controls⁶⁴. The lack of correlation between central adiposity and limb fat loss argues for separate processes for determining peripheral lipoatrophy and central adiposity^{63,64}.

The studies addressing non-antiretroviral factors of central adiposity in HIV-positive patients are also hampered by the lack of a consensus definition and by differences in the design and populations studied. Non-antiretroviral factors reported to be associated with a higher risk for central adiposity in HIV-positive persons are older age^{60,65}, female gender^{59,60,65}, white race⁶⁰, higher body fat⁶⁰, less exercise⁵⁹, and lower CD4⁺ cell count^{60,66}.

Consequences of visceral adipose tissue in HIV-positive patients

The metabolic and morphologic changes observed in persons with HIV infection receiving cART show considerable overlap with diagnostic criteria for the metabolic syndrome, a constellation of abnormalities^{14,15} that lead to an increased risk of CV disease and DM in the general population.

Recent epidemiological data collected from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study shows an increasing prevalence of the metabolic syndrome over six years from 2000 to 2007⁶⁷.

Observational studies suggest an increased risk of CV disease among HIV-positive patients compared with the general population⁶⁸ and an increased risk of myocardial infarction in HIV-positive persons with each year of cART exposure, particularly to the PI class^{69,70}. Traditional CV risk factors, such as smoking, dyslipidemia, and impaired glucose tolerance, are more common among HIV-positive patients and contribute similarly to CV events⁷¹. The contribution of emerging CV risk biomarkers to risk in HIV is less established.

Silent plaque imaging assessed by coronary calcium score (CAC) is associated with total coronary atherosclerotic disease burden. The CAC score is a strong predictor of subsequent CV disease and recently it has been shown that slowing the coronary artery calcification process will translate into a reduced risk of events (as previously demonstrated with regression of luminal stenosis in angiographic trials)⁷². An observational cross-sectional study of 372 HIV-positive patients receiving cART found a CAC score > 10 in 134 patients (36%), with a median CAC score of 50 (range 10-1243). Lipotrophy alone (OR: 3.82; 95% CI: 1.11; 13.1), fat accumulation alone (OR: 7.65; 95% CI: 1.71; 37.17) and mixed lipodystrophy phenotypes (OR: 4.36; 95% CI: 1.26; 15.01) were strongly associated with the presence of CAC after adjusting for age, sex, hypertension, and cumulative exposure to ART⁷³. The prospective extension of this study, analyzing predictors of progression of CAC in 132 patients who underwent two sequential CT scans (median follow-up time of 333 days), showed that CAC progression was independently related to older age, higher LDL, higher CD4⁺ lymphocytes, and greater VAT⁷⁴.

Thus, increased VAT in HIV-positive patients is associated with surrogate markers of CV disease and atherosclerosis progression.

Both DM and insulin resistance (IR) are more prevalent in the HIV-positive population⁷⁵ and these

changes in glucose homeostasis are associated with CV risk^{76,77}.

In antiretroviral-naive, HIV-positive patients with or without coinfection with hepatitis C virus, the prevalence of IR is about 12%^{78,79}. As with the general population, in HIV-positive individuals there is an independent relationship of upper trunk and visceral adipose tissue with IR⁸⁰.

Relative growth hormone deficiency has been described in patients with HIV-associated central fat accumulation⁸¹. Among HIV-positive patients, reduced pulse height and overnight growth hormone concentrations are most strongly associated with increased visceral adiposity⁸¹⁻⁸³. Reduced growth hormone secretion is independently associated with dyslipidemia, higher glucose and C-reactive protein among HIV-positive patients with abdominal fat accumulation⁸⁴.

Central adiposity and increased VAT diminishes health-related quality of life through erosion of self-esteem and decreased social functioning⁸⁵. Patient dissatisfaction about body image may lead to anxiety and depression as well as sexual dysfunction⁸⁶⁻⁸⁸. Dissatisfaction with body shape may unfavorably impact adherence to cART⁸⁹.

Changes in visceral adiposity with antiretroviral therapy initiation and switch

Advanced, untreated HIV infection is associated with proatherogenic dyslipidemia, including low HDL and raised triglycerides⁹⁰, together with raised resting energy expenditure, weight loss, and cachexia^{91,92}. Commencement of effective antiretroviral therapy is associated with a restoration to health in the depleted compartments, including a rise in lean mass and trunk and limb fat⁹³. Use of antiretroviral regimens containing the thymidine analog reverse transcriptase inhibitors zidovudine (AZT) and stavudine (d4T) is associated with subsequent subcutaneous and limb fat loss⁹³. Metabolic changes precede body composition changes and appear at best only partially correlated with morphologic abnormalities^{94,95}. The prospective ACTG384/5005s study noted that while individuals showed diverse patterns of fat gain and loss over 64 weeks after initiation of cART, the changes tended to occur in the same direction. Changes in waist and hip circumferences correlated positively ($r = 0.62$; $p < 0.001$). In this study, the proportion of subjects with WHR more than 0.95 (men) or 0.90 (women) was 34% at baseline and 47% at week 64 ($p = 0.003$). In those

who developed increased WHR, 76% had increased waist circumference⁹⁶.

The impact of specific drug choices on body composition is incomplete, particularly with regard to visceral adiposity, but has been investigated using a variety of techniques in comparative studies of nucleoside reverse transcriptase inhibitors (NRTI), PI, and “class-sparing” regimens. The data point to differences between drugs within the same class and across classes as well as an influence over baseline health status, such as CD4⁺ cell count and BMI, on changes in body composition.

Comparisons between nucleoside reverse transcriptase inhibitors

Thymidine analog-based regimens are associated with subcutaneous and peripheral limb fat loss relative to thymidine-sparing⁹³ and NRTI-sparing therapy⁹⁷.

The FIRST and ABCDE studies documented differences between d4T and abacavir (ABC) based regimens. In the FIRST study, which used anthropometry, the didanosine (ddI) plus d4T arm saw declines in both waist and hip circumferences, the decline being more rapid for the hip circumference, resulting in the WHR actually increasing. An opposite effect was seen with the ABC plus lamivudine (3TC) arm, with both circumferences increased, but more slowly for the waist circumference, resulting in a declining WHR⁹⁸.

In the ABCDE study, fewer ABC recipients were clinically assessed as having lipo-accumulation (10.7 vs. 24.7% with d4T; $p = 0.023$). The ABC recipients had greater weight increases to week 96 (4.7 vs. 2.25 kg), reflecting a marked decline in limb fat seen in the d4T group. A significantly smaller increase in the WHR was observed in the ABC group as compared to the group receiving d4T (1.2 vs. 4.5%; $p = 0.002$). This difference was driven by a significant increase in waist girth in both arms accompanied by an increase in hip girth only in the ABC arm⁹⁹.

Nonrandomized data from a large cohort followed by anthropometric measurements support the assertion that thymidine analog-based regimens are associated with waist circumference increases whereas ABC is not¹⁰⁰.

Studies GS903 and GS934 each lacked baseline morphology assessments. In GS934, among patients who had DXA scans at weeks 48 and 96, limb fat was lower and declining in the AZT/3TC arm and rose in the tenofovir (TDF)/emtricitabine (FTC) arm. Through 96 weeks, patients receiving TDF/FTC had a significantly greater

median increase from baseline in weight of 2.7 kg compared with 0.5 kg in patients receiving ZDV/3TC ($p < 0.001$). Truncal fat by DXA at week 96 was higher with TDF/FTC (10.4 kg) compared with AZT/3TC (8.6 kg) ($p = 0.053$)¹⁰¹.

Comparison between protease inhibitors

The BASIC trial study randomized 120 ARV-naive patients to saquinavir/ritonavir (SQV/r) 2,000/100 mg daily, or atazanavir/ritonavir (ATV/r) 300/100 mg daily, both combined with TDF/FTC. The ATV/r subjects experienced significant increases from baseline in lean body mass, limb fat, SAT, and VAT, with a significantly greater increase in limb fat ($p = 0.03$) and VAT ($p = 0.04$) in the ATV/r arm compared with the SQV/r arm¹⁰². Similar observations were seen in the CASTLE lipodystrophy substudy. Total weight as well as limb, subcutaneous and visceral fat increased in both groups. Changes in subjects' body composition were influenced by baseline CD4⁺ cell count, BMI, and randomized group. In low BMI ($< 22 \text{ kg/m}^2$) patients, ATV/r resulted in significantly greater gain in SAT and VAT compared to lopinavir/ritonavir (LPV/r). A trend to greater limb fat gain was also seen in the subjects with ATV/r compared to LPV/r. In patients with advanced HIV disease (CD4⁺ cell counts $< 50 \text{ cells/mm}^3$) ATV/r resulted in a significantly greater gain in limb fat and SAT compared to LPV/r. In higher BMI ($> 27 \text{ kg/m}^2$) patients, trends to greater gains in SAT and limb fat were seen with LPV/r compared to ATV/r¹⁰³. These data suggest that both PI choice and baseline characteristics influence observed body composition changes.

Nucleoside reverse transcriptase inhibitor-sparing regimens and newer regimens

In the MEDICLAS study, the AZT/3TC plus LPV/r group experienced progressive limb fat loss, whereas abdominal fat increased, exclusively in the visceral compartment ($+21.9 \pm 8.1 \text{ cm}^2$; $p = 0.008$). In contrast, the nevirapine (NVP) plus LPV/r group saw a generalized increase in fat mass, supporting the role for thymidine analogs in VAT increase¹⁰⁴. In the Abbot 613 study, the mean trunk fat increased from baseline to week 96, both in subjects randomized to LPV/r monotherapy (after a 24-week induction with additional AZT/3TC) or efavirenz (EFV) plus AZT/3TC. At week 96, the proportion of subjects with lipoatrophy was significantly lower in the LPV/r treatment group than in the EFV treatment

group (5 vs. 34%, respectively; $p < 0.001$), whereas the proportion of subjects with lipohypertrophy did not differ between the two treatment groups (45 vs. 44%, respectively; $p > 0.99$)¹⁰⁵. In the ACTG 5142 study, which compared three class-sparing strategies, trunk fat increased from a median of 8.2 kg (IQR: 5.0-12.2) at entry to 10.4 kg (IQR: 6.8-14.4) at week 96. There were no significant differences at weeks 48 or 96 by randomized treatment or NRTI selection in either percentage change in trunk fat or percentage of subjects with more than 20% gain in trunk fat. Similarly, in the FIRST study, the mean change in visceral tissue area from baseline was significant and sustained, with no differences between NRTI plus PI, nonnucleoside reverse transcriptase inhibitor (NNRTI) or PI plus NNRTI strategies¹⁰⁶.

In subjects receiving raltegravir or EFV over 48 weeks in the StartMRK study, both groups saw similar increases in total, appendicular, and truncal fat by DXA¹⁰⁷.

Switching antiretrovirals to reduce visceral adipose tissue

Variable responses have been seen in changes in VAT or truncal fat following antiretroviral switch. The lack of improvement in visceral fat mass with switch suggests several possibilities. Weight gain after initiation of cART is well recognized and may represent a restoration to health phenomenon. Visceral adiposity and the metabolic syndrome are common events in the general population. Once established, visceral adiposity may be a self-sustaining event, a vicious cycle in the majority of patients. The lack of improvement in visceral fat after treatment switch may, therefore, indicate a limited role of antiretroviral drug choice in the majority of individuals with visceral adiposity.

However, benefits have been seen in selected patients. In a study of 15 patients with marked abdominal adiposity and hyperinsulinemia, decreases in VAT and improved glucose uptake by muscle were observed following switch from LPV/r to ATV/r¹⁰⁸. A larger study, however, of PI/r to ATV/r switch, which based entry on abdominal circumference, did not show benefit¹⁰⁹. Other PI replacement studies have seen similar outcomes. Replacement of a PI with ABC¹¹⁰, NVP¹¹¹, or EFV^{111,112} did not improve visceral adiposity.

Thymidine analog substitution studies involving switch of NRTI for the management of lipohypertrophy have shown different outcomes on visceral adiposity. While two studies did not show any benefit^{113,114}, in ACTG 5110 a switch from d4T or AZT to a non-thymidine

analog or to a NRTI-sparing regimen was associated with qualitatively similar improvements in thigh fat, SAT, and VAT:TAT ratio at 48 weeks. Reductions in VAT were seen in the group that switched to ABC¹¹⁵.

Exercise, diet, and oral interventions for central fat accumulation in HIV-patients

Exercise and diet

Studies assessing the effects of exercise in HIV-positive patients with central fat accumulation indicate mixed results. Most studies suffer from limitations such as short duration, small patient numbers, and variability in inclusion criteria. Case-control data suggest that diets higher in total protein and dietary fiber and performing more resistance training are associated with a lower risk of central adiposity (defined as WHR > 0.95)¹¹⁶.

Once central adiposity is established, several studies show benefits on central fat accumulation through a combined program of diet, aerobic exercise, and progressive resistance training^{117,118}. Uncontrolled data in men demonstrated that 16 weeks of exercise leads to a 2% decrease in total body fat from baseline (1.5 kg; $p < 0.01$), mostly occurring in the trunk¹¹⁸. Comparing exercise versus no exercise in HIV-positive women with fat accumulation, a randomized study revealed a modest reduction in waist circumference in the exercise group, but no change in total fat or VAT¹¹⁷. A four-month light aerobic exercise program in patients with documented fat accumulation was associated with preferential and significant loss of VAT (-12% versus baseline) and significant improvements in total and HDL cholesterol and triglycerides¹¹⁹.

Exercise and dietary interventions have been investigated in HIV-positive patients presenting with general obesity or metabolic syndrome. In 30 HIV-positive individuals with lipohypertrophy and a mean baseline WHR from 0.91-0.94 receiving a low-fat diet, a 12-week exercise program had no additional effect compared with stretching and relaxation on body fat, body weight, or WHR¹²⁰. However, a 12-week study of a reduced-calorie diet combined with aerobic and resistance exercise in 18 HIV-positive women with general obesity led to significant reductions in waist circumference (-6.1 cm; $p < 0.001$) but not WHR. The volumes of both VAT (-17%) and SAT (-15%) declined significantly, whereas VAT:SAT ratio, glucose and lipids did not change significantly¹²¹. A randomized study of observation versus intensive lifestyle intervention, comprising

weekly one-on-one counseling sessions focusing on reducing saturated fats, increasing fiber, and walking, evaluated 34 HIV-positive subjects with metabolic syndrome. At six months, subjects assigned to lifestyle intervention experienced a mean 2.6 cm decrease in waist circumference ($p < 0.05$ versus baseline and control group), as well as significant improvements in systolic blood pressure and hemoglobin A1c, but not lipid levels, fasting glucose, or IR¹²².

Broadly, data suggest well supported diet and exercise regimens are worthwhile in the prevention and management of central adiposity in HIV-positive persons.

Testosterone

A randomized, placebo-controlled, 24-week trial of 10 g testosterone gel or placebo given to 88 HIV-positive men with increased WHR (> 0.95) or waist circumference (> 100 cm) demonstrated that testosterone therapy in patients with abdominal obesity was not associated with a significantly greater reduction in visceral fat mass. However, total body, trunk, abdominal SAT, and appendicular fat mass decreased to a greater extent in the testosterone group than in the placebo group. These changes in abdominal fat mass in the testosterone-treated men were associated with greater reductions in waist circumference and WHR and in perceptions of change in abdomen size than those observed in the placebo group¹²³.

Antidiabetic medications

Treatment with thiazolidinediones, such as rosiglitazone or pioglitazone, has been studied in HIV-positive patients. Although some of these studies showed modest improvement in peripheral lipoatrophy upon assessment by DXA¹²⁴⁻¹²⁶, this was not confirmed in other studies^{127,128}. Importantly, none of these studies showed a beneficial effect on VAT when assessed by MRI or CT^{124,125,127,128}. Similarly, therapy with metformin appears to have inconsistent effects on visceral fat accumulation in HIV-positive patients¹²⁹⁻¹³¹. One randomized, placebo-controlled study in 26 HIV-positive patients with signs of IR and evidence of truncal fat accumulation found that metformin 500 mg given twice daily significantly reduced insulin levels on oral glucose challenge¹²⁹, and was associated with significant reductions in weight, waist circumference, and a trend toward reduced VAT ($-1,115$ vs. $1,191$ mm²; $p = 0.08$, a decline of approximately 7% in the metformin group).

However, there was also a decrease in mean SAT as compared to placebo treatment and the WHR did not change significantly. In another small, randomized, placebo-controlled study, which enrolled HIV-positive patients with self-reported increases in abdominal girth and with excess WHR, 24 weeks of treatment with metformin had no effect on VAT, but significantly reduced limb fat¹³⁰. Taken together, these findings suggest that in treating visceral fat accumulation, metformin should be reserved for patients with impaired glucose tolerance or DM and no evidence of lipoatrophy. A recent study of combining metformin with rosiglitazone, compared with either monotherapy, in the treatment of HIV-positive patients with hyperinsulinemia and elevated WHR found no significant differences between treatment groups regarding changes in abdominal VAT¹³¹. Finally, combining metformin treatment with exercise training for three months was more effective than metformin alone in reducing median WHR and both abdominal SAT and VAT¹³². In the metformin-only group, VAT area had minimally increased, but decreased by 17 cm² in the metformin plus exercise group ($p = 0.063$).

Injectable therapies for visceral adiposity

Both recombinant human growth hormone (rhGH) and the growth hormone releasing hormone (GHRh) analog, tesamorelin, have been studied in HIV-positive individuals with increased waist circumference.

Growth hormone therapy is approved by the FDA but not by the European Medicines Evaluation Agency for AIDS-related wasting, where it improves muscle mass and physical performance¹³³. Recent studies of pharmacologic doses of growth hormone have shown a consistent reduction in visceral adiposity in HIV-positive patients, but highly supra-physiologic levels of insulin-like growth factor 1 (IGF-1) and symptoms of growth hormone excess, such as glucose intolerance, fluid retention, arthralgia, and myalgia, resulted in an excess of discontinuations^{134,135}. Of note, combination of rhGH with rosiglitazone appears to abrogate the negative effects on glucose metabolism¹²⁶.

Twelve weeks of rhGH at a dose of 4 mg daily led to a 20.3% mean reduction in VAT, whereas the placebo group showed no change ($+3.6\%$; $p < 0.001$). The rhGH group also had a 20% reduction in trunk fat, 7.1% reduction in abdominal SAT, and 6.0% reduction in limb fat by DXA. In contrast, the placebo group showed gains in trunk fat, abdominal SAT, and limb fat (1.4, 1.6, and 2.8%, respectively; $p < 0.001$ for each between-group difference)¹³⁵.

Other smaller studies have shown similar effects¹³⁶⁻¹³⁸ although a 6 mg rhGH daily dose resulted in a mean VAT decrease of 42% ($n = 24$; $p < 0.001$), whereas only a 15% decline in VAT was seen with 4 mg every other day ($n = 10$; $p < 0.01$) after 12 weeks, with trends toward further decreases after an additional 12 weeks at each dose. Tolerability was poor, however, with joint pain, muscle pain, and new onset DM observed. Body composition rebounded to or near baseline after a 12-week washout period¹³⁹.

Lower, more physiological doses of rhGH have also been tested in growth hormone-deficient abdominally obese persons with HIV. In a randomized, 56-patient, double-blind, placebo-controlled trial, subjects received either rhGH or matching placebo titrated to the upper quartile of normal IGF-1 range for 18 months. The starting dose of rhGH was 2 $\mu\text{g}/\text{kg}/\text{day}$ and increased to maximum dose of 6 $\mu\text{g}/\text{kg}/\text{day}$ (average dose, 0.33 mg/day). The VAT area decreased significantly in the rhGH group compared with the placebo group (treatment effect, -19 cm^2 ; 95% CI: -38 to -0.5 cm^2 ; $p = 0.049$), which corresponds with a percentage change in VAT of -8.5% in the rhGH group and -1.6% in the placebo group. Adverse event rates were similar and lipid parameters improved, but two-hour glucose levels on glucose tolerance testing were increased by rhGH¹⁴⁰.

Two large, 26-week, randomized studies of tesamorelin versus placebo in individuals with visceral adiposity have been performed, with crossover designs allowing both the effects of a further 26 weeks of therapy and the effects of withdrawal of therapy to be observed. In the first study, which enrolled 412 HIV-positive individuals, VAT decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. Other favorable effects were seen with triglycerides decreased by 50 mg/dl with tesamorelin versus an increase of 5 mg/dl in the placebo group, and the ratio of total cholesterol to HDL cholesterol decreased by 0.31 and increased by 0.21, respectively ($p < 0.001$ for all comparisons). Levels of total cholesterol and HDL cholesterol also improved significantly in the tesamorelin group. Levels of IGF-1 increased by 81.0% in the tesamorelin group and decreased by 5.0% in the placebo group ($p < 0.001$). Adverse events did not differ significantly between the two study groups, although hypersensitivity to tesamorelin has been occasionally reported¹⁴¹.

At week 26 of tesamorelin, the change in VAT was -18.1% compared to baseline. Patients who stopped tesamorelin regained VAT so that after 26 weeks off therapy VAT was -1.6% compared to baseline¹⁴². In the

second, similar study, which enrolled 404 HIV-positive individuals, tesamorelin decreased VAT by -10.9% (-21 cm^2) vs. -0.6% (-1 cm^2) in the placebo group in the six-month efficacy phase ($p < 0.0001$). Trunk fat ($p < 0.001$), waist circumference ($p = 0.02$), and WHR ($p = 0.001$) improved, with no change in limb or abdominal subcutaneous fat. Insulin-like growth factor-1 increased ($p < 0.001$), but no change in glucose parameters was observed. Patient rating of belly appearance distress ($p = 0.02$), and physician rating of belly profile ($p = 0.02$) were significantly improved in the tesamorelin vs. placebo-treated groups. The drug was well tolerated¹⁴³.

The effects of tesamorelin appear to be highly specific for the visceral-fat compartment, with relatively little effect on subcutaneous fat or fat in limbs. This preferential reduction in VAT is important, given that peripheral lipoatrophy is commonly also present. The reductions in visceral adiposity observed correlated with the degree of baseline visceral adiposity, larger effects being seen among patients with more accumulation of visceral fat.

Recombinant human leptin (r-metHuLeptin) has also been evaluated in a small randomized, placebo-controlled, double-blinded, crossover study in seven HIV-positive men with lipoatrophy, serum leptin level less than 3 ng/ml, and fasting triglyceride level greater than 300 mg/dl. Compared with placebo, r-metHuLeptin therapy improved fasting insulin levels, IR (by HOMA), and high-density lipoprotein. Body weight and fat mass decreased on r-metHuLeptin, mainly due to a decrease in truncal fat but not peripheral fat or lean body mass. Measurement of VAT was not performed. In addition, r-metHuLeptin was well tolerated, and HIV control was not adversely affected¹⁴⁴. These data suggest further investigation of leptin is warranted.

Conclusions and summary

Increased abdominal fat accumulation, particularly VAT, is increasingly recognized in aging populations and is contributing to increased CV disease and type 2 DM. Increased VAT is commonly associated with multiple metabolic abnormalities as part of the "metabolic syndrome". Selective surgical removal of a small amount of visceral fat improves metabolic risk factors, whereas liposuction to remove considerable subcutaneous fat has little effect^{145,146}.

HIV-positive individuals appear to commonly develop increased VAT and the metabolic syndrome after the initiation of a range of antiretroviral regimens. Increased

upper trunk and visceral fat have been shown to correlate most strongly with IR and dyslipidemia in HIV-positive patients^{53,80,95}. Recent data in HIV-positive patients receiving cART suggest increased VAT is significantly associated with progression of coronary calcium scores^{73,74}. The adverse effects of increased waist circumference shown in HIV-negative patients may be greater among HIV-positive patients, in whom waist circumference is made up of increased VAT with loss of SAT, as opposed to HIV-negative patients, with obesity and excess VAT and SAT. Therefore, there may be a particularly strong logic to selectively reducing VAT in the HIV population.

Diet and exercise should be considered a routine part of HIV care, with evidence supporting both a preventative role in central fat accumulation as well as therapeutic effect on central adiposity and some metabolic parameters. Data on antiretroviral drug choice, especially with current regimens, are limited although differences in effects on metabolic parameters are better defined. Some observed changes in body composition may represent restoration to health, with greater increases in fat, both visceral and subcutaneous, occurring in those with most advanced disease and lowest fat mass at baseline¹⁰³. Switching between antiretrovirals does not lead to consistent improvements in VAT although selected subjects, such as those on a thymidine analog or with documented IR on a PI, may benefit. Similarly, additional agents such as metformin may benefit selected subjects with documented IR and no peripheral lipoatrophy. Testosterone supplementation has a more limited role.

Injectable therapies, rhGH, and tesamorelin appear to provide the most consistent benefits in reducing VAT and improving distress around abdominal adiposity. A dosage of rhGH 4 mg/day is associated with a 20% decline in VAT over 12 weeks, but with fluid retention side effects (myalgia, arthralgia, edema, carpal tunnel syndrome) characteristic of elevated IGF-1 levels as well as glucose intolerance¹³⁵. More physiological dosing of rhGH (0.3 mg/day) is better tolerated but has only modest (–7%) effects on VAT¹⁴⁰. Tesamorelin 2 mg/day reduces VAT by 15–18% over 26 weeks and appears well tolerated, even in diet-controlled patients with DM, and does not lead to supra-physiological exposures of IGF-1^{141–143}. In each case, VAT appears to rebound after drug discontinuation so further work on maintenance approaches is needed.

In summary, abdominal adiposity and increased VAT are common problems in persons with HIV. They are associated with metabolic disorders and progression

of coronary artery plaques. Management options appear limited at present, although new injectable agents hold considerable promise.

Conflict of Interests

Dr. Moyle has received research grants from Abbott, Ardea Biosciences, Bionor, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies, and Tibotec. He has received honoraria as speaker and/or advisor from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies, Tibotec and ViiV Healthcare. Dr. Moutschen has received research grants and honoraria as speaker and/or advisor for Theratechnologies. Dr. Domingo has received research grants from Abbott, Gilead Sciences, GlaxoSmithKline, Pfizer, and Tibotec. He has received honoraria as speaker and/or advisor from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies, and Tibotec. Dr. Guaraldi has received research grants from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Boehringer-Ingelheim, Theratechnologies, and Tibotec. He has received honoraria as speaker and/or advisor from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies, and Tibotec. Dr. Raffi has received honoraria for speaking engagements, advisory board membership and consultancy, as well as research grants from companies including Abbott, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies, and Tibotec. Prof. Behrens has received grant support by the German Research Foundation, the Minister for Education and Research, the H.W. & J. Hector Foundation, Bristol-Myers Squibb, and Abbott. He received honoraria as speaker and/or advisor from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies and Tibotec. Dr. Reiss has received honoraria for speaking engagements, advisory board membership and consultancy, as well as research grants from companies including Boehringer Ingelheim, Hoffmann-La Roche, Merck, Tibotec, Gilead Sciences, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb and Theratechnologies.

References

1. Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. *Lancet*. 1997;349:1819.
2. Munk B. Protease paunch? *Posit Aware*. 1997;8:20-1.

3. Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. *AIDS*. 1998;12:2499.
4. Koppel K, Bratt G, Rajs J. Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. *AIDS*. 1999;13:1993-4.
5. Hamilton B, Paglia D, Kwan A, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. *Nat Med*. 1995;1:953-6.
6. Kern P, Saghizadeh M, Ong J, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J Clin Invest*. 1995;95:2111-19.
7. Wajchenberg B. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev*. 2000;21:697-738.
8. Vague P. The distinction of android and gynoid obesities as the base for their prognosis. *Sem Hop*. 1955;31:3503-9.
9. Balkau B, Deanfield J, Després J, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. *Circulation*. 2007;116:1942-51.
10. Lu M, Ye W, Adami H, Weiderpass E. Prospective study of body size and risk for stroke amongst women below age 60. *J Intern Med*. 2006;260:442-50.
11. Joy T, Keogh H, Hadigan C, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. *J Acquir Immune Defic Syndr*. 2008;47:174-84.
12. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. *J Acquir Immune Defic Syndr*. 2008;48:142-8.
13. Fox K, Després J, Richard A, et al. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulatory patients in 27 European Countries. *Eur Heart J*. 2009;30:3055-63.
14. http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-97.
16. Brown T, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multi-center AIDS Cohort Study. *AIDS Res Ther*. 2009;13:6-8.
17. Schoen R, Evans R, Sankey S, Weissfeld J, Kuller L. Does visceral adipose tissue differ from subcutaneous adipose tissue in fatty acid content? *Int J Obes Relat Metab Disord*. 1996;20:346-52.
18. Ross R, Shaw K, Rissanen J, et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. *Am J Clin Nutr*. 1994;59:1277-85.
19. Ross R. Magnetic resonance imaging provides new insights into the characterization of adipose and lean tissue distribution. *Can J Physiol Pharmacol*. 1996;74:778-85.
20. Baumgartner R, Heymsfield S, Roche A, Bernardino M. Abdominal composition quantified by computed tomography. *Am J Clin Nutr*. 1988;48:936-45.
21. Janssen I, Ross R. Effects of sex on the change in visceral, subcutaneous adipose tissue and skeletal muscle in response to weight loss. *Int J Obes Relat Metab Disord*. 1999;23:1035-46.
22. Ross R, Leger D, Morris D. Quantification of adipose tissue by MRI: relationship with anthropometric variables. *J Appl Physiol*. 1992;72:787-95.
23. Ross R, Shaw K, Martel Y, et al. Determination of total and regional adipose tissue distribution by magnetic resonance imaging in android women. *Basic Life Sci*. 1993;60:177-80.
24. Ross R, Shaw K, Martel Y, de Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. *Am J Clin Nutr*. 1993;57:470-5.
25. Koester R, Hunter G, Snyder S, Khaled M, Berland L. Estimation of computerized tomography derived abdominal fat distribution. *Int J Obes Relat Metab Disord*. 1992;16:543-54.
26. Liu K, Chan Y, Chan W, et al. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. *Int J Obes Relat Metab Disord*. 2003;27:1267-73.
27. Abate N, Burns D, Peshock R, Garg A, Grundy S. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. *J Lipid Res*. 1994;35:1490-6.
28. He Q, Engelson E, Wang J, et al. Validation of an elliptical anthropometric model to estimate visceral compartment area. *Obes Res*. 2004;12:250-7.
29. Yang G, Myerson S, Chabat F, Pennell D, Firmin D. Automatic MRI adipose tissue mapping using overlapping mosaics. *MAGMA*. 2002;14:39-44.
30. Poll L, Wittsack H, Koch J, et al. Quantification of total abdominal fat volumes using magnetic resonance imaging. *Eur J Med Res*. 2002;7:347-52.
31. Poll L, Wittsack H, Koch J, et al. A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. *Magn Reson Imaging*. 2003;21:631-6.
32. Shen W, Punyanitya M, Wang Z, et al. Visceral adipose tissue: relations between single-slice areas and total volume. *Am J Clin Nutr*. 2004;80:271-8.
33. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol*. 2004;97:2333-8.
34. Han T, Kelly I, Walsh K, Greene R, Lean M. Relationship between volumes and areas from single transverse scans of intra-abdominal fat measured by magnetic resonance imaging. *Int J Obes Relat Metab Disord*. 1997;21:1161-6.
35. Thomas E, Bell J. Influence of undersampling on magnetic resonance imaging measurements of intra-abdominal adipose tissue. *Int J Obes Relat Metab Disord*. 2003;27:211-18.
36. Williams M, Hunter G, Kekes-Szabo T. Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. *Int J Obes Relat Metab Disord*. 1996;20:613-17.
37. Elbers J, Haumann G, Asscheman H, Seidell J, Gooren LJ. Reproducibility of fat area measurements in young, non-obese subjects by computerized analysis of magnetic resonance images. *Int J Obes Relat Metab Disord*. 1997;21:1121-9.
38. Seidell J, Bakker C, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution—a comparison between computed tomography and 1.5-T magnetic resonance. *Am J Clin Nutr*. 1990;51:953-7.
39. Staten M, Totty W, Kohrt W. Measurement of fat distribution by magnetic resonance imaging. *Invest Radiol*. 1989;24:345-9.
40. Gerard E, Snow R, Kennedy D, et al. Overall body fat and regional fat distribution in young women: quantification with MR imaging. *Am J Roentgenol*. 1991;157:99-104.
41. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. *Arteriosclerosis*. 1990;10:493-6.
42. van der Kooy K, Seidell J. Techniques for the measurement of visceral fat: a practical guide. *Int J Obes Relat Metab Disord*. 1993;17:187-96.
43. Minocci A, Savia G, Lucantoni R, et al. Leptin plasma concentrations are dependent on body fat distribution in obese patients. *Int J Obes Relat Metab Disord*. 2000;24:1139-44.
44. Hashimoto M, Akishita M, Eto M, et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. *Int J Obes Relat Metab Disord*. 1998;22:477-84.
45. Suzuki R, Watanabe S, Hirai Y, et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. *Am J Med*. 1993;95:309-14.
46. Yamamoto M, Egusa G, Hara H, Yamakido M. Association of intra-abdominal fat and carotid atherosclerosis in non-obese middle-aged men with normal glucose tolerance. *Int J Obes Relat Metab Disord*. 1997;21:948-51.
47. Vlachos I, Hatzioannou A, Perelas A, Perrea D. Sonographic assessment of regional adiposity. *Am J Roentgenol*. 2007;189:1545-53.
48. Park Y, Heymsfield S, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? *Int J Obes Relat Metab Disord*. 2002;26:978-83.
49. Rush E, Chandu V, Plank L. Prediction of fat-free mass by bioimpedance analysis in migrant Asian Indian men and women: a cross validation study. *Int J Obes (Lond)*. 2006;30:1125-31.
50. Pateyjohns I, Brinkworth G, Buckley J, et al. Comparison of three bioelectrical impedance methods with DXA in overweight and obese men. *Obesity*. 2006;14:2064-70.
51. Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. *Diabetes Care*. 2005;28:451-3.
52. Mulligan K, Glesby M, Freedland E. Sex differences in the correlations between baseline anthropometric measurements and fat distribution in HIV-infection-associated adipose redistribution (HARS). *Antivir Ther*. 2007;12(suppl 2):L27.
53. Scherzer R, Shen W, Bacchetti P, et al. Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging-measured adipose tissue depots in both HIV-infected and control subjects. *Am J Clin Nutr*. 2008;87:1809-17.
54. Caan B, Armstrong M, Selby J, et al. Changes in measurements of body fat distribution accompanying weight change. *Int J Obes Relat Metab Disord*. 1994;18:397-404.
55. Carr A, Emery S, Law M, et al. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. *Lancet*. 2003;361:726-35.
56. Savés M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. *Clin Infect Dis*. 2002;34:1397-405.

57. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. *J Acquir Immune Defic Syndr*. 2002;31:50-5.
58. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. *J Acquir Immune Defic Syndr*. 2003;34:58-61.
59. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. *HIV Med*. 2003;4:293-301.
60. Jacobson D, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. *Clin Infect Dis*. 2005;40:1837-45.
61. Cofrancesco J, Freedland E, McComsey G. Treatment options for HIV-associated central fat accumulation. *AIDS Patient Care STDS*. 2009;23:5-18.
62. Poizot-Martin I, Obry-Roguet V, Biron C, et al. Abdominal adiposity remains highly prevalent in French HIV-infected patients having initiated antiretroviral therapy after 2005. *EACS 2009*; Cologne, Germany [abstract PS11/1].
63. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. *J Acquir Immune Defic Syndr*. 2005;40:121-31.
64. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. *J Acquir Immune Defic Syndr*. 2006;42:562-71.
65. Martínez E, Mocroft A, García-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. *Lancet*. 2001;357:592-8.
66. Lichtenstein K. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. *J Acquir Immune Defic Syndr*. 2005;39:395-400.
67. Worm S, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS*. 2010;24:427-35.
68. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. *J Clin Endocrinol Metab*. 2007;92:2506-12.
69. Friis-Møller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*. 2003;349:1993-2003.
70. Friis-Møller N, Reiss P, Sabin C, et al. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med*. 2007;356:1723-35.
71. Currier J, Lundgren J, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. *Circulation*. 2008;118:e29-35.
72. Budoff M, Shaw L, Liu S, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. *JACC*. 2007;49:1860-70.
73. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in HIV infected subjects. *Atherosclerosis*. 2010;208:222-7.
74. Guaraldi G, Zona S, Orlando G, et al. Progression of subclinical atherosclerosis in HIV Infected Patients. *ADRLH-45*. 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. October 2009, Philadelphia, USA.
75. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. *Clin Infect Dis*. 2001;32:130-9.
76. Bonora E, Kiechi S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population. *Diabetes Care*. 2007;30:318-24.
77. Hanley A, Williams K, Stern M, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. *Diabetes Care*. 2002;25:1177-84.
78. Visnegarwala F, Chen L, Raghavan S, et al. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients coinfecting with hepatitis C virus (HCV) and HIV-1 compared to patients without coinfection. *J Infect*. 2005;50:331-7.
79. Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin resistance in treatment-naïve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. *Antivir Ther*. 2006;11:529-35.
80. Grunfeld C, Rimland D, Gibert C, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. *J Acquir Immune Defic Syndr*. 2007;46:283-90.
81. Rietsche P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. *J Clin Endocrinol Metabolism*. 2001;86:504-10.
82. Koutkia P, Eaton K, You S, et al. Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. *AIDS*. 2006;20:855-62.
83. Koutkia P, Meininger G, Canavan B, et al. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. *Am J Physiol Endocrinol Metab*. 2004;286:E296-303.
84. Lo J, You S, Wei J, Canavan B, Grinspoon S. Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. *Clin Endocrinol (Oxf)*. 2009 [epub ahead of print].
85. Guaraldi G, Murri R, Orlando G, et al. Lipodystrophy and quality of life of HIV-infected persons. *AIDS Rev*. 2008;10:152-61.
86. Luzi K, Guaraldi G, Murri R, et al. Body image is a major determinant of sexual dysfunction in stable HIV-infected women. *Antivir Ther*. 2009;14:85-92.
87. Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. *Antivir Ther*. 2007;12:1059-65.
88. Luzi K, Guaraldi G, Murri R, et al. Body image is a major determinant of sexual dysfunction in stable HIV-infected women. *Antivir Ther*. 2009;14:85-92.
89. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. *HIV Clin Trials*. 2003;4:99-106.
90. Grunfeld C, Kotler D, Shigenaga J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. *Am J Med*. 1991;90:154-62.
91. Macallan D, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. *N Engl J Med*. 1995;333:83-8.
92. Macallan D, Noble C, Baldwin C, et al. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. *Am J Clin Nutr*. 1993;58:417-24.
93. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. *AIDS*. 2003;17:971-9.
94. Calmy A, Carey D, Mallon PW, et al. Early changes in adipokine levels and baseline limb fat may predict HIV lipodystrophy over 2 years following initiation of antiretroviral therapy. *HIV Med*. 2008;9:101-10.
95. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. *J Acquir Immune Defic Syndr*. 2008;48:44-52.
96. Mulligan K, Parker R, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. *J Acquir Immune Defic Syndr*. 2006;41:590-7.
97. Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS*. 2009;23:1109-18.
98. Shlay J, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naïve patients randomized to didanosine and stavudine vs. abacavir and lamivudine. *J Acquir Immune Defic Syndr*. 2005;38:147-55.
99. Podzamczar D, Ferrer E, Sanchez P, et al. Less lipodystrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. *J Acquir Immune Defic Syndr*. 2007;44:139-47.
100. Shlay J, Sharma S, Peng G, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2009;51:298-304.
101. Pozniak A, Gallant J, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes—a 96-week analysis. *J Acquir Immune Defic Syndr*. 2006;43:535-40.
102. Vroenraets S, Fernandez Garcia E, Jackson A, et al. Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofovir/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial. *EACS 2009*; Cologne, Germany [abstract LBPS10/6].
103. Moyle G, Yang R, Wirtz V, et al. Body composition changes in treatment-naïve patients treated with boosted PIs plus TDF/FTC: results from the CASTLE study through 96 weeks. *EACS 2009*; Cologne, Germany [abstract LBPS 11/6].
104. van Vonderen M, van Aagtmael M, Hassink E, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. *PLoS One*. 2009;4:e5647.
105. Cameron D, da Silva B, Arribas J, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. *J Infect Dis*. 2008;198:234-40.
106. Shlay J, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. *J Acquir Immune Defic Syndr*. 2007;44:506-17.
107. DeJesus E, Lazzarin A, Lennox A, et al. Metabolic profiles and body composition changes in treatment-naïve HIV-infected patients treated with raltegravir 400 mg bid-based vs. efavirenz 600 mg qhs-based combination therapy: 48-week data. *ICAAC 2009*. H-329.
108. Stanley T, Joy T, Hadigan C, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. *AIDS*. 2009;23:1349-57.

109. Moyle G, Girard J-M, Andrade J, et al. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. XVII International AIDS Conference, Mexico City, 2008; [abstract MOPDB103].
110. Moyle G, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipodystrophy. *J Acquir Immune Defic Syndr*. 2003;33:22-8.
111. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. *AIDS*. 2005;19:917-25.
112. Moyle G, Baldwin C, Comitis S, et al. Management of metabolic and body shape changes occurring during protease inhibitor (PI) therapy by substitution of PI with efavirenz in virologically controlled HIV-1 positive persons: A single arm observational cohort. *J Acquir Immune Defic Syndr*. 2001;28:399-401.
113. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipodystrophy: a randomized trial. *JAMA*. 2002;288:207-15.
114. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipodystrophy. *AIDS*. 2006;20:2043-50.
115. Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipodystrophy: results of ACTG A5110. *J Antimicrob Chemother*. 2009;63:998-1005.
116. Hendricks K, Dong K, Tang A, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. *Am J Clin Nutr*. 2003;78:790-5.
117. Dolan S, Frontera W, Librizzi J, et al. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. *Arch Intern Med*. 2006;166:1225-31.
118. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. *AIDS*. 1999;13:1373-5.
119. Thoni G, Fedou C, Brun J, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. *Diabetes Metab*. 2002;28:397-404.
120. Terry L, Sprinz E, Stein R, et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. *Med Sci Sports Exerc*. 2006;38:4111-17.
121. Engelson E, Agin D, Kenya S, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. *Metabolism*. 2006;55:1327-36.
122. Fitch K, Anderson E, Hubbard J, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. *AIDS*. 2006;20:1843-50.
123. Bhasin S, Parker R, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. *J Clin Endocrinol Metab*. 2007;92:1049-57.
124. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. *Ann Intern Med*. 2004;140:786-94.
125. Slama L, Lanoy E, Valantin M, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). *Antivir Ther*. 2008;13:67-76.
126. Macallan D, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. *HIV Clin Trials*. 2008;9:253-67.
127. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipodystrophy: randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;363:429-38.
128. Sutinen J, Hakkinen A, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. *Antivir Ther*. 2003;8:199-207.
129. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. *JAMA*. 2000;284:472-7.
130. Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. *HIV Med*. 2007;8:420-6.
131. Mulligan K, Yang Y, Wininger D, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. *AIDS*. 2007;21:47-57.
132. Driscoll S, Meininger G, Lareau M, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. *AIDS*. 2004;18:465-73.
133. Moyle G, Daar E, Gertner J, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2004;35:367-75.
134. Kotler D, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2004;35:239-52.
135. Grunfeld C, Thompson M, Brown S, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. *J Acquir Immune Defic Syndr*. 2007;45:286-97.
136. Luzi L, Meneghini E, Oggionni S, et al. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. *Eur J Endocrinol*. 2005;153:781-9.
137. Bickel M, Zangos S, Jacobi V, et al. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. *HIV Med*. 2006;7:397-403.
138. Andersen O, Haugaard S, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. *Eur J Clin Invest*. 2004;34:561-8.
139. Engelson E, Glesby M, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. *J Acquir Immune Defic Syndr*. 2002;30:379-91.
140. Lo J, You S, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. *JAMA*. 2008;300:509-19.
141. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. *N Engl J Med*. 2007;357:2359-70.
142. Falutz J, Allas S, Mamputu J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. *AIDS*. 2008;22:1719-28.
143. Falutz J, Potvin D, Mamputu J-C, et al. Effects of Tesamorelin, a growth hormone releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized, placebo-controlled, trial with a safety extension. *J Acquir Immune Defic Syndr*. 2010 [Epub ahead of print].
144. Lee J, Chan J, Sourlas E, Raptopoulos V, Mantzoros C. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipodystrophy and metabolic syndrome induced by the highly active antiretroviral therapy. *J Clin Endocrinol Metab*. 2006;91:2605-11.
145. Klein S, Fontana L, Young V, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. *N Engl J Med*. 2004;350:2549-57.
146. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. *Int J Obes Relat Metab Disord*. 2002;26:193-9.